Drug Trial Radar · NCT04961710
Extension Study of Hetrombopag in Severe Aplastic Anemia
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
157
Actual
Start
Sep 19, 2019
Primary completion
Nov 30, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with treatment-naive severe aplastic anemia. All subjects who have completed or withdrawn from the HR-TPO-SAA-III study will voluntarily participate in this extension study. Subjects will receive the same study drug (hetrombopag or placebo) as in study HR-TPO-SAA-III, with the same doses and administration schedule or with modifications based on the actual conditions. The primary objective of this extension study is to give the subjects participating in the HR-TPO-SAA-III study the continued access to the study drug (hetrombopag or placebo) after the completion of the HR-TPO-SAA-III study.
Conditions
- Treatment-naive Severe Aplastic Anemia
Interventions
Hetrombopag OlamineDrug
Hetrombopag Olamine; once daily
PlaceboDrug
Placebo; once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ratio of subjects with clonal evolution at 6 months and 18 monthsTime frame: 6 months and 18 months
- All SIEs, regardless of whether they are related to the investigational productTime frame: 3 years
- All SAEs, regardless of whether they are related to the investigational productTime frame: 3 years
- All AEs resulting in discontinuation and withdrawal from studyTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.